Illumina
Overview

Date:
15th January 2025, Wednesday

Time:
12:00 pm - 01:00 pm (Dubai)
01:30 pm - 02:30 pm (Delhi)
04:00 pm - 05:00 pm (Singapore)
05:00 pm - 06:00 pm (Seoul / Tokyo)
06:00 pm - 07:00 pm (Melbourne)

Register Now
We understand that our webinar timing may not suit your busy schedule. Please feel free to register to get the on-demand recording link once it is ready.

Noninvasive Prenatal Testing (NIPT) is a screening test based on the analysis of cell-free DNA from maternal blood. Through a simple maternal blood draw, NIPT can noninvasively screen for fetal chromosomal aneuploidies as early as the 10th week of pregnancy. Genome-wide screening offers insights into partial duplications and deletions across all autosomes, as well as the aneuploidy status of all chromosomes. This webinar will cover the fundamentals of NIPT, including the underlying technology and key technical aspects of the test.

Speaker:

Farah Abdel Rahman-
Senior Technical Application Scientist,
Illumina Inc.

Farah obtained her PhD in gene editing and viral-based gene therapy from the Technical University of Munich. She completed a master's degree in physiology and holds a bachelor's degree in biology from the American University of Beirut. Farah started her career at the Lebanese American University as a faculty fellow, where she taught graduate courses in biotechnology.

In 2022, Farah joined Illumina, where she currently provides support for NIPT and BeadArray workflows. Additionally, she is a certified Infinium trainer.
Register below to join us at the webinar.
Company Legal
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.